Journal article

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer

Emma Nolan, Peter Savas, Antonia N Policheni, Phillip K Darcy, Francois Vaillant, Christopher P Mintoff, Sathana Dushyanthen, Mariam Mansour, Jia-Min B Pang, Stephen B Fox, Charles M Perou, Jane E Visvader, Daniel HD Gray, Sherene Loi, Geoffrey J Lindeman

Science translational medicine | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2017

Grants

Awarded by Australian National Health and Medical Research Council (NHMRC)


Awarded by NHMRC Fellowship


Awarded by NCI Breast SPORE program


Awarded by NHMRC Australia Fellowship


Awarded by NHMRC Elizabeth Blackburn Research Fellowship


Awarded by NHMRC Career Development Fellowship-2


Funding Acknowledgements

This work was supported by the Australian National Health and Medical Research Council (NHMRC) (grants 1016701, 1040978, and 1078763), the NHMRC Independent Research Institute Infrastructure Support Scheme (IRIISS), the Victorian State Government through the Victorian Cancer Agency and Operational Infrastructure Support, the Breast Cancer Research Foundation (New York), the Qualtrough Cancer Research Fund, the Joan Marshall Breast Cancer Research Fund, and the Australian Cancer Research Foundation. E.N. was supported by a Cancer Council Victoria Scholarship and a Cancer Therapeutics CRC Top-Up Scholarship. A.N.P. was supported by a Cancer Council Victoria Scholarship. P.K.D. was supported by NHMRC Fellowship 1041828. S.B.F. was supported by NHMRC Fellowship 1079329. C.M.P. was supported by funds from the NCI Breast SPORE program (P50-CA58223-09A1 and RO1-CA195740-01). J.E.V. was supported by NHMRC Australia Fellowship 1037230 and is currently supported by NHMRC Elizabeth Blackburn Research Fellowship 1102742. D.H.D.G. was supported by NHMRC Career Development Fellowship-2 (1090236). S.L. was supported by a John Colebatch Cancer Council Victoria Clinical Fellowship. G.J.L. was supported by NHMRC Fellowship 1078730.